Maurice Slevin

Last updated
Maurice Slevin
CitizenshipUnited Kingdom
Education University of Cape Town
OccupationOncologist
Known for Cancerbackup
Medical career
Research Oncology

Maurice Slevin is a British medical oncologist specialising in the treatment of breast, ovarian and gastrointestinal cancers. [1] He has made contributions to the field through both his clinical practise and research. [2] He practised at St Bartholomew's Hospital and was a founding partner of Leaders in Oncology Care (LOC) on Harley Street. [3] [4]

Contents

Education

Slevin graduated from the University of Cape Town and completed his postgraduate training at Groote Schuur Hospital in Cape Town and St Bartholomew's Hospital in London, where he worked as head of chemotherapy for solid cancers. [5] [6] [7] He is a Fellow of the Royal College of Physicians.

Career

His research primarily focused on clinical pharmacology, with particular emphasis on etoposide and cytosine arabinoside, as well as psychosocial oncology. [3] [8] [9] [10] He has published over 150 peer-reviewed papers in academic journals and has an h-index of 58. [11] [12]

He helped establish the cancer support charity Cancerbackup, which he chaired from 1985 to 2008, when it merged with Macmillan. [13] [14] [15] [16]

Slevin and his colleagues carried out a study, funded by the Imperial Cancer Research Fund, which showed that cancer patients were more likely to opt for radical and intensive treatment with minimal chance of benefit than were their doctors. [17]

Slevin gained attention for his controversial papers on the National Health Service (NHS), where he argued that reform was more crucial than increased funding. [2] [18] [19] He suggested that the NHS had almost as many managers as nurses, a claim that was slammed by the NHS federation. [20] He led a movement in 2000 demanding a wholesale overhaul of NHS treatment of the disease, along with Karol Sikora, in which they argued for faster cancer treatment timelines. [21]

Slevin was a founder member of Doctors for Reform, a group of 1000 consultants who advocated a social insurance model of funding the NHS. [22]

Publications

Slevin has over 150 published peer-reviewed papers in academic journals, including: [23] [11]

Related Research Articles

<span class="mw-page-title-main">Altretamine</span> Chemical compound

Altretamine, also called hexamethylmelamine, is an antineoplastic agent. It was approved by the U.S. FDA in 1990.

<span class="mw-page-title-main">Naptumomab estafenatox</span>

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.

<span class="mw-page-title-main">Tamibarotene</span> Chemical compound

Tamibarotene, also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL). It is currently marketed only in Japan and early trials have demonstrated that it tends to be better tolerated than ATRA. Tamibarotene has been tested in many other cancer types, including Acute Myeloid Leukemia where it shows no benefit, and lung cancer, where it accelerated the cancer growth and increased mortality.

Growth factor receptor inhibitors are drugs that target the growth factor receptors of cells. They interfere with binding of the growth factor to the corresponding growth factor receptors, impeding cell growth and are used medically to treat cancer.

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.

The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, where the compound being evaluated is an immuno-oncology drug. Immuno-oncology, part of the broader field of cancer immunotherapy, involves agents which harness the body's own immune system to fight cancer. Traditionally, patient responses to new cancer treatments have been evaluated using two sets of criteria, the WHO criteria and the response evaluation criteria in solid tumors (RECIST). The immune-related response criteria, first published in 2009, arose out of observations that immuno-oncology drugs would fail in clinical trials that measured responses using the WHO or RECIST Criteria, because these criteria could not account for the time gap in many patients between initial treatment and the apparent action of the immune system to reduce the tumor burden.

<span class="mw-page-title-main">Branimir Ivan Sikic</span> American physician

Branimir Ivan "Brandy" Sikic is an American medical doctor and scientist at Stanford University School of Medicine. He is an oncologist and cancer pharmacologist, and has served as a faculty member at Stanford University since 1979. His research spans basic, translational, and clinical research and investigates the mechanisms of drug resistance and the development of new anticancer therapies.

Masofaniten, also known by its developmental code name EPI-7386, is an N-terminal domain antiandrogen, or antagonist of the N-terminal domain (NTD) of the androgen receptor (AR), which is under development for the treatment of prostate cancer. The compound was developed as a successor of previous drugs in the EPI series such as EPI-001, ralaniten (EPI-002), and ralaniten acetate (EPI-506). Masofaniten shows 20-fold higher antiandrogenic potency than ralaniten in vitro (IC50Tooltip Half-maximal inhibitory concentration = 535 nM vs. 9,580 nM, respectively), as well as greater stability in human hepatocytes. It was planned to enter phase I clinical trials in 2020. Preliminary results of a phase I/II clinical trial were published in 2023.

Sally Barrington is a professor of positron emission tomography (PET) Imaging and National Institute for Health Research (NIHR) research professor at King's College London (KCL), England, United Kingdom. She joined KCL in 1993.

Christopher Hourigan is a physician-scientist known for work on measurable residual disease in acute myeloid leukemia.

Kimmie Ng is a physician at Dana–Farber Cancer Institute who is known for her work on colorectal cancer in young patients.

Beth Ann Overmoyer is an American physician and oncologist. She is Director of the Inflammatory Breast Cancer Program at the Dana–Farber Cancer Institute.

<span class="mw-page-title-main">Defactinib</span> Pharmaceutical

Defactinib is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors.

Patrick J. Loehrer is an American oncologist who is Indiana University Distinguished Professor, Joseph W. and Jackie J. Cusick Professor in Oncology, Professor of medicine, Indiana University School of Medicine; Director emeritus, Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Deborah Schrag is the George H. Bosl Chair at Memorial Sloan Kettering Cancer Center. She is a medical oncologist known for her work in patient care and examination of patient outcomes.

Faith Gibson is a British nurse who is Deputy Chief Nurse for Research, Nursing and Allied Health and Professor of Child Health and Cancer Care at Great Ormond Street Hospital. Her research investigates cancer care for children and young people. She was awarded the International Society of Paediatric Oncology Lifetime Achievement Award in 2018.

Ronald de Wit is a professor of medical oncology at Erasmus University Medical Center in Rotterdam, Netherlands. He is the founding chairman of the Dutch Uro-Oncology Study Group (DUOS).

<span class="mw-page-title-main">TNP-470</span> Chemical compound

TNP-470 is an methionine aminopeptidase 2 inhibitor. Although it was one of the first angiogenesis inhibitor tested in clinical trials, its potential was hampered by neurotoxic effects and lack of effectiveness.

Telisotuzumab vedotin is a monoclonal antibody developed by AbbVie for non-small cell lung cancer.

References

  1. ↑ Slevin, Maurice L. (2003). Resuscitating the NHS (PDF). Centre for Policy Studies. ISBN   1-903219-50-7.
  2. 1 2 "NHS could implode say doctors". BBC NEWS. 2003-02-03. Retrieved 2024-09-09.
  3. 1 2 "How doctors care for their own families' futures". The Telegraph. 2016-02-23. Retrieved 2024-09-09.
  4. ↑ Slevin, Maurice L. (2015). Every Rational Attempt: The Stories Behind The Contribution of Barts In The Fight Against Cancer (PDF). London: Barts Cancer Institute, Queen Mary University of London. ISBN   978-1-326-33764-3.
  5. ↑ "Reunions held in 2013: Class of 1973 reunion". UCT Faculty of Health Sciences. Retrieved 2024-09-09.
  6. ↑ "Team". Fcancer. Retrieved 2024-09-09.
  7. ↑ "St. Bartholomew's and Royal London Hospitals (Hansard, 6 July 1993)". api.parliament.uk. 1993-07-06. Retrieved 2024-09-09.
  8. ↑ Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PF (September 1989). "A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer". Journal of Clinical Oncology. 7 (9): 1333–40. doi:10.1200/JCO.1989.7.9.1333. PMID   2549204.
  9. ↑ Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA (September 1983). "Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid". Journal of Clinical Oncology. 1 (9): 546–51. doi:10.1200/JCO.1983.1.9.546. PMID   6583325.
  10. ↑ Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, Downer SM (June 1990). "Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public". BMJ (Clinical Research Ed.). 300 (6737): 1458–60. doi:10.1136/bmj.300.6737.1458. PMC   1663147 . PMID   2379006.
  11. 1 2 "Maurice Slevin". Google Scholar. Retrieved 2024-09-09.
  12. ↑ "Massachusetts General Hospital and other places". ResearchGate. 2008-04-01. Retrieved 2024-09-09.
  13. ↑ Slevin ML, Terry Y, Hallett N, Jefferies S, Launder S, Plant R, Wax H, McElwain T (September 1988). "BACUP--the first two years: evaluation of a national cancer information service". BMJ (Clinical Research Ed.). 297 (6649): 669–72. doi:10.1136/bmj.297.6649.669. PMC   1834344 . PMID   3140928.
  14. ↑ "The history of Macmillan". Macmillan Cancer Support. Retrieved 2024-09-09.
  15. ↑ Lake, Howard (2008-01-12). "Macmillan Cancer Support and Cancerbackup to merge". UK Fundraising. Retrieved 2024-09-09.
  16. ↑ Cornish, Jenny (2010-07-16). "Mergers: Who's the leader of the brand?". Third Sector. Retrieved 2024-09-09.
  17. ↑ Read, Cathy (1994-02-15). "Health: When is it time to give in to cancer?: Some doctors believe". The Independent. Retrieved 2024-09-09.
  18. ↑ Carvel, John (2003-02-04). "NHS on brink of implosion, claims leading specialist". The Guardian. Retrieved 2024-09-09.
  19. ↑ "NHS is crushed by red tape, say consultants". The Telegraph. 2003-02-04. Retrieved 2024-09-09.
  20. ↑ "Managers fight back over consultants claims". Public Finance. 2003-02-06. Retrieved 2024-09-09.
  21. ↑ Templeton, Sarah-Kate (2007-08-26). "Experts push NHS to use US style cancer care". The Times & The Sunday Times. Retrieved 2024-09-09.
  22. ↑ "Calls for 'NHS tax' to finance health care". The Telegraph. 2007-06-02. Retrieved 2024-09-09.
  23. ↑ "Maurice Slevin". PubMed. Retrieved 2024-09-09.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.